* Novo to update full-year outlook end-October (Adds diabetes research details, possible sale, analyst comment, updates shares)
the inflammatory diseases space after discontinuing anti-IL-20 for the treatment of rheumatoid arthritis, Novo Nordisk (NYSE: NVO ) decides to discontinue its R&D efforts in the area. EVP and CSO Mads Krogsgaard Thomsen says, "The discontinuation
COPENHAGEN, Sept 2 (Reuters) - Danish pharmaceutical group Novo Nordisk said it aims to either sell or license out drugs from its inflammatory unit, a part of the business which it had decided to drop..
COPENHAGEN, Sept 2 (Reuters) - Danish pharmaceutical company Novo Nordisk said on Tuesday it has decided to stop its activities within inflammatory disorders and only focus on the treatment and prevention of diabetes and obesity.
COPENHAGEN, Sept 1 (Reuters) - Novo Nordisk has launched its type 2 diabetes treatment Ryzodeg in Mexico, a combination drug that could reap the company billions in revenues in years to come.
pharma names including Sanofi, Lilly, AbbVie, Bayer AG, Bristol-Myers-Squibb, GlaxoSmithKline, AstraZeneca, Novo Nordisk , and Amgen. Gilead is rapidly approaching the market cap of the two largest US pure pharma companies, Pfizer and Merck
Aug 27 (Reuters) - Novo Nordisk A/S says: ** Has announced the acquisition of a manufacturing facility in West Lebanon, New Hampshire, USA, from Olympus
famously, Denmark is also home to Novo Nordisk (NYSE: NVO ), the world's largest player ..... more than 20% year-to-date, Novo Nordisk has now surpassed GlaxoSmithKline ..... earnings Over the past ten years, Novo Nordisk 's annualized growth rate of
underlying risks to an investment in China Biologic, given that the plasma space is home to Baxter (NYSE: BAX ) and Novo Nordisk (NYSE: NVO ), which market internationally ADVATE and NovoSeven, NovoEight and NovoThirteen, respectively. Nevertheless
to continue supporting the dividend payments.Lilly has been steadily losing share in the insulin market because of Novo Nordisk 's more effective marketing and the success of its long-acting and rapid-acting insulin analogs.The patent loss